Steven Barag, DO
Family Medicine · Rancho Cucamonga, CANPI 1366444838
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 40.6% of the total. Reporting peaked in 2021 at $26,513 and has fallen 88.7% since, to $2,997 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,330 payments — averaging $64.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$35K
- Eli Lilly$14K
- AstraZeneca$8K
- Pfizer$6K
- Acerus Pharmaceuticals Corporation$4K
- Novo Nordisk$2K
- plus $17K from 54 others
Across 895 payments — averaging $1960.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$894K
- Pfizer$163K
- AstraZeneca$151K
- Novo Nordisk AS$143K
- AbbVie$140K
- Bayer$113K
- plus $151K from 9 others
What the payments were for
- Consulting fees$8,51610%
- Speaking & faculty fees$34,42040%
- Travel & lodging$16,53719%
- Food & beverage$25,55930%
- Education$2530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$85,285 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 262 | $239,343 |
| MounjaroTirzepatide | 203 | $225,266 |
| FarxigaDapagliflozin Propanediol | 161 | $152,877 |
| OzempicSemaglutide | 129 | $123,552 |
| RybelsusSemaglutide | 75 | $89,187 |
| EliquisApixaban | 84 | $78,926 |
| TrulicityDulaglutide | 34 | $50,432 |
| GemtesaVibegron | 62 | $49,053 |
| Nurtec OdtRimegepant Sulfate | 26 | $46,678 |
| JanuviaSitagliptin Phosphate | 59 | $46,355 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $45,715 |
| KerendiaFinerenone | 50 | $40,022 |
| MyrbetriqMirabegron | 28 | $27,396 |
| LinzessLinaclotide | 33 | $26,438 |
| VascepaIcosapent Ethyl | 35 | $25,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $601 | $275,698237 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $552 | $262,693291 claims |
| Novo NordiskOzempic, Rybelsus | $1,976 | $212,739204 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $7,676 | $191,445213 claims |
| PfizerEliquis, Nurtec Odt | $6,064 | $125,603110 claims |
| MerckJanuvia, Janumet Xr | $280 | $60,78376 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $460 | $60,54086 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $273 | $49,05362 claims |
| BayerKerendia | $1,162 | $40,02250 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $329 | $27,63061 claims |
| Astellas Pharma US IncMyrbetriq | $270 | $27,39628 claims |
| AbbVieLinzess | $34,593 | $26,43833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Rancho Cucamonga
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.